

ISSN: 2278 – 0211 (Online)

Efficacy Of The Cow Milk In The Increasing Of CD4 For People Living With HIV

Sahaha Jean Bosco

Medical Directorate, The Munini Hospital, Nyaruguru, Rwanda **Edgar Colon Lancara**

Department Of Public Health, School Of Social And Human Studies Atlantic International University, Hawaii, The United States Of America

Manzi Olivier

Department Of Internal Medicine, Faculty Of Medicine The National University Of Rwanda, Huye, Rwanda

Abstract:

There are People Living with HIV (PLWHIV) who are poor. Those PLWHIV who are eligible to antiretroviral (ARV) drugs, get them free of charge, but their CD4 don't increase. The ARV, only, are not enough to increase CD4 for People Living with HIV. Meanwhile, the cow milk is a complete nutrient and it has several proteins which inhibit the enzymes of HIV. So the cow milk can increase rapidly CD4 for PLWHIV. On the other hand, there is a policy in Rwanda of "One cow per family" which has started. This policy aims at giving one cow to every family which is in need of it, in Rwanda. 1 liter of cow milk per day for 3 months was given to a study group of people living with HIV chosen randomly while a control group didn't receive the cow milk. There was a significant association statistically between consuming the cow milk and rapid increasing of CD4 with a threshold α =0.05, P=0.0012.

Kev words: Cow milk CD4

1. Introduction

There is a major problem of People Living with HIV (PLWHIV) especially the poor ones, who don't have enough increasing of CD4 while they are on ART (Antiretroviral therapy). So ARV drugs only are not enough to increase CD4 for People Living with HIV.

Meanwhile, the cow milk which inhibits HIV enzymes by its 8 proteins such as lactoferrin, alpha lactalbumin, beta lactoglobulin, casein, glycolactin, angiogenin1, lactogenin, lactoperoxidase and is a complete nutrient with its water (90%), proteins (3-4g/100g), carbohydrates (4.8-5.2g/100g), fats (3.5-6g/100g), minerals like Potassium 138mg/100ml, calcium 125mg/100ml, Chlorine 103mg/100ml, Phosphorus 96mg/100ml, Sodium 50mg/100ml, Sulfur 30 mg/100ml, Magnesium 12 mg/100ml, micro minerals, including Cobalt, Copper, Iron 0.1 mg/100g, Manganese, Molybdenum, Zinc, Selenium, Iodine 22 mg/l; and vitamins like Vitamin A 39µg/100g, Vitamin B1 0.05mg/100g, Vitamin B12 0.17mg/100g, Vitamin C 0.6mg/100g, Vitamin D 0.03µg/100g, Vitamin E 0.07mg/100g, Vitamin PP-Pellagra Preventing Factor 0.16mg/100g, Vitamin B5 0.35mg/100g, Vitamin B9 3µg/100g, Vitamin K1 17µg/dl, Folic Acid 37.7µg/dl, Osmolarity 23mosm/dl; the cow milk has 750 kilocalories/liter. (7), (8), (9), (10), (11), (17), (18), (22), (25), (26), (28). On the other hand, there is in Rwanda a National Policy called: "One cow per family" which makes possible the availability of cow milk.

When I arrived at the MUNINI Hospital in October 2010, I found that 58% of all People Living with HIV on ART had less than 500 CD4 and 3 PLWHIV died in 2010, 4 died in 2011, according to Health Management Information System at the MUNINI Hospital of 2011, (HMIS 2011) and I remembered that I did in 2008 a study which showed the efficacy of the cow milk in the increasing of CD4 for people living with HIV and I decided to do the study in the NYARUGURU District, particularly at the MUNINI Hospital.

2. Materials and Methods

2.1. Materials

The fresh cow milk was purchased from local suppliers. That cow milk was boiled and given to participants in the study group. Facscount machine helped us to measure CD4 and Taqman system to have viral load. An electronic weighing scale helped us to measure the weight of participants and we used a height measuring stick for their height. A questionnaire was used for social, economic and demographic characteristics of the participants. The Stata/IC-11.0 was used for statistical analysis.

2.2. Study Type

This study is evaluative of an intervention. This means that there is an evaluation of an intervention which is about giving the cow milk to People Living with HIV. This intervention has an impact to the People Living with HIV especially in increasing their CD4.

2.3. Study Design

It is a randomized controlled trial. Participants were chosen randomly and they were in 2 groups. Those in the study group received 1 liter of cow milk per day for 3 months while participants in the control group didn't receive that cow milk.

2.4. Sample Design

The sampling design in this study is simple random sampling and any participants among all 24 enrolled in the study had the same chance to be selected.

2.5. Period Of The Study

The study started on August 09, 2012 and ended on November 14, 2012.

2.6. Method Itself

Based on a randomized controlled trial and simple random sample design, among a group of 24 People Living with HIV with similar socio-economic and clinical characteristics, two groups of 12 People Living with HIV each were randomly allocated, one to receive the cow milk as a study group and the other to not receive the cow milk as a control group.

In the study group there were 12 adults living with HIV, indigents, treated with ART since at least 6 months with CD4 count below 500/mm³. All were living in the NYARUGURU District in Rwanda and used to consult the ART department at the MUNINI Hospital. They didn't have any allergy and/or intolerance on the cow's milk and they accepted to consume the cow milk.

In the control group, there were 12 adults Living with HIV, indigents, treated with ART since at least 6 months with CD4 count below 500/mm³. All were living in the NYARUGURU District in Rwanda and, like participants in the study group; they used to consult the ART department at the MUNINI Hospital. Some of them had allergy and/or intolerance on the cow's milk. Others told us that they didn't like to drink it. Finally, others could drink it but they could not afford to buy one liter a day for three months because of poverty. One liter of the cow milk had a price of about \$0.56. Participants were indigents and they could not afford to pay themselves such amount of money.

We managed to measure CD4, Viral load and weight as well as body mass index for all participants both in the study group and in the control group at the beginning and the end of the study.

3.Results

In the study group we had twelve people living with HIV and three of them equivalent to twenty- five percent had beyond 500 CD4/mm³, seven of them equivalent to fifty-eight percent had from 350 up to 500 CD4/mm³ and two participants equivalent to seventeen percent had between 200 and 349 CD4/mm³. No one had less than 200 CD4/mm³ at the end of the study.

In the control group we had twelve people living with HIV. No one had beyond 500 CD4/mm³. Three participants who were equivalent to twenty-five percent had from 350 CD4/mm³ up to 500 CD4/mm³; eight participants who were equivalent to sixty-seven percent had from 200CD4/mm³ up to 349 CD4/mm³ and one participant in the control group who was equivalent to eight percent had less than 200 CD4/mm³.




Figure 1




Figure 2

. ttest co	l4i, by(gro	oup)				
Two-sample	t test wi	th equal var	iances			
Group	Obs	Mean	Std. Err.	Std. Dev.	[95% Conf.	Interval]
1 2	12 12	331.4167 329.3333	32.91989 31.62142	114.0378 109.5398	258.9605 259.7351	403.8729 398.9316
combined	24	330.375	22.3228	109.3589	284.1968	376.5532
diff		2.083333	45.64683		-92.5824	96.74907
diff = Ho: diff =	= mean(1) - = 0	mean(2)		degrees	t of freedom	
	iff < 0 = 0.5180	Pr(Ha: diff != T > t) =			iff > 0) = 0.4820

Table 1: Value Of Mean, Standard Deviation And P Relating To The CD4 Count By Groups At The Beginning Of The Study

-> group =	1					
Paired t t	est					
Variable	Obs	Mean	Std. Err.	Std. Dev.	[95% Conf.	Interval]
cd4i cd4ii	12 12	331.4167 451.4167	32.91989 30.73382	114.0378 106.4651	258.9605 383.772	403.8729 519.0613
diff	12	-120	27.83474	96.42237	-181.2638	-58.73615
Ha: mean(Pr(T < t) -> group =	= 0.0006		: mean(diff) T > t) =			(diff) > 0) = 0.9994
Pr(T < t)	= 0.0006					
Pr(T < t) -> group =	= 0.0006) = 0.9994
Pr(T < t) -> group = Paired t t	= 0.0006 2 est	Pr(T > t) =	0.0012	Pr(T > t) = 0.9994
Pr(T < t) -> group = Paired t t Variable cd4i	= 0.0006 2 est Obs	Pr(Mean 329.3333	T > t) = Std. Err. 31.62142	0.0012 Std. Dev. 109.5398	Pr(T > t) [95% Conf. 259.7351	Interval] 398.9316

Table 2: Value Of Mean, Standard Deviation And P Relating To CD4 By Groups At The End Of The Study (P<0.05 For The Study Group)

4.Discussion

The people living with HIV, in the study group, who consumed one liter of cow milk per day for three months had an increasing of CD4 of about one hundred and twenty CD4 per cubic millimeter (120 CD4/mm³) on average within only three months, while the people living with HIV in the control group, who didn't consume the cow milk within three months, leaving in similar sociodemographic conditions with similar characteristics like the participants in the study group, had a decreasing of CD4 of about twenty-nine CD4 per cubic millimeter (29 CD4/mm³) within three months.

The results showed that there was a significant association statistically between consuming the cow milk and rapid increasing of CD4 with a threshold α =0.05, P=0.0012

A laboratory limitation in measuring the viral load below 20RNA copies/ml characterized the results.

The results showed that there was a significant association statistically between consuming cow milk and rapid increasing of the weight with a threshold α =0.05, P=0.0000

The results showed that there was a significant association statistically between consuming the cow milk and rapid increasing of body mass index with a threshold α =0.05, P=0.0001

5.References

- 1. Baker, E., Rumball, S., Anderson, B. (1987). Transferrins: insights into structure and function from studies on lactoferrin. Trends in Biochemistry Science.
- 2. Baveye, S., Elass, E., Mazurier, J., Legrand, D. (2000). Lactoferrin inhibits the binding of lipopolysaccharides to L-selectin and subsequent production of reactive oxygen species by neutrophils. FEBS letters.
- 3. Berkahout, B., Derksen, G., Back, N. (1997) et all. Structural and functional analysis of negatively charged milk proteins with anti-HIV activity. Department of human retrovirology, Academic Medical center, University of Amsterdam (Eds). The Netherlands.

- 4. Blomkalns, A., Gomez, M. (1997). Purification of bovine alpha-lactalbumin by immobilized metal ion affinity chromatography. Preparative Biochemistry and Biotechnology.
- 5. Brock, J. H., (1997). Regulation of lymphocyte proliferation. In: T. W. Hutchens, B. Lonnerdahl (Eds), Lactoferrin. Interactions and Biological Functions, Humana Press, Totoua, NJ.
- 6. Ellison, R. T.III, (1994). The effects of lactoferrin on gram-negative bacteria. In: T. C. V. Hutchens, S. V. Rumball, B. Lonnerdahl (Eds), Lactoferrin: Structure and Function, Plenum Press, New York.
- 7. Floren, C., Chinenye, S., Elfstrand, L., et all. (2006). Coloplus, a new product based on bovine colostrums, alleviates HIV-associated diarrhea. Department of internal medicine, Lund University Hospital (Eds). Lund, Sweden.
- 8. Goff, D. (2010). Dairy Chemistry and Physics. Dairy Science and Technology University of Guelph
- 9. Groot, F., Geijtenbeek, T., Sanders, R., et all. (2005). Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type1 transmission by blocking the DC-SIGN-gp120interaction. Department of human retrovirology, academic medical center University of Amsterdam(Eds). Amsterdam, The Netherlands.
- 10. Konlee, M. (1998). Sulphated polysaccharides (chondritin sulphate and carrageenan) plus glucosamine sulphate are potent inhibitors of HIV.s.l.
- 11. Hamsen, M., Swart, P., de Bethune, M., et all. (1995). Antiviral effects of plasma and milk proteins. Lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. Department of immunology, University of Groningen (Eds). The Netherlands.
- 12. Matousek, J., Soucek, J., Riha, J., Zankel, T., Benner, S. (1988). Immunosuppressive activity of angiogenin in comparison with bovine seminal ribonuclease and pancreatic ribonuclease. Comparative Biochemistry and Physiology.
- 13. Lam, T., Lam, M., Au, T., et all. (2000). A comparison of human immunodeficiency virus type 1 protease inhibition activities by the aqueous and methanol extracts of Chinese medicinal herbs. Life Sciences.
- 14. Ministry of Health (MOH) [Rwanda], National Institute of Statistics of Rwanda (NISR), and ICF Macro. 2009. Rwanda Interim Demographic and health Survey 2007-08. Calverton, Maryland, U.S.A.: MOH, NISR, and ICF Macro.
- 15. Neurath, A., Debnath, A., Strick, N., et all. (1995). Blocking of CD4 cell receptors for the human immunodeficiency virus type 1(HIV-1) by chemically modified bovine milk proteins. Laboratory of biochemical virology, Lindsley F, Kimbell Research institute of New York Blood Center(Eds). New York, USA.
- 16. Neurath, A., Jiang, S., Strick, N., et all. (1996). Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nature Medicine.
- 17. Ng, T., Lam, T., Au, T., et all. (2001). Inhibition of human immunodeficiency virus type 1 reverse transcriptase, protease and integrase by bovine milk proteins. Department of biochemistry, The Chinese University of Hong Kong (Eds). Shatin, Hong Kong, China.
- 18. Ng, T., ¿Ye, X. (2004). A polymeric immunoglobulin receptor-like milk protein with inhibitory activity on human immunodeficiency virus type 1 reverse transcriptase. Department of biochemistry, Faculty of Medicine, The Chinese University of Hong Kong(Eds). Shatin, Hong Kong, China.
- 19. Ng, T., Huang, B., Fong, W., Yeung, H. (1997). Anti-human immunodeficiency virus (anti-HIV) natural products with special emphasis on HIV reverse transcriptase inhibitors. Life Sciences.
- 20. Olson, K., Fett, J., French, T., et all. (1995). Angiogenin antagonists prevent tumor growth in vivo. Proceedings of the National Academy of Sciences of the United States of America.
- 21. Olson, K., French, T., Vallee, B., et all. (1994). A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Research.
- 22. Pehrsson et al (2000). USDA's National Food and Nutrient Analysis Program: Food Sampling. JOURNAL OF FOOD COMPOSITION AND ANALYSIS.
- 23. Puddu, P., Borghi, P., Gessani, S. (1998) et all. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1infection.Laboratory of Immunoloy,Istituto Superiore di Sanita(Eds). Rome, Italy.
- 24. Ramussen, L., Petersen, T. (1991). Purification of disulphide-linked alpha s2- and kappa-casein from bovine milk. Journal of Dairy Research.
- 25. Swart, P., Kuipers, E., Smit, C., et all. (1998). Lactoferrin antiviral activity of Lactoferrin. Department of Pharmacology, University of Groningen (Eds). The Netherlands.
- 26. Swart, P., Kuipers, M., Smit, C., et all. (1996). Antiviral effects of milk proteins:acylation results in polyanionic compounds with potent activity against human immunodeficiency virus type 1 and type 2 in vitro. Department of pharmaceutical pharmacology and clinical pharmacy, University Centre for Pharmacology (Eds). Groningen, The Netherlands.
- 27. Viani, R., Gutteberg, T., Lathey, J., et all. (1999). Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with Zidovudine. AIDS.
- 28. Wang, H., Ye, X., [£]Ng, T. (2000). First demonstration of an inhibitory activity of milk proteins against human immunodeficiency virus-1 reverse transcriptase and the effect of succinylation. Department of microbiology, China Agricultural University (Eds). Beijing, China.
- 29. Willman, J., Martins, T., Jaskowski, T., et all. (1999). Heterophile antibodies to bovine and caprine proteins causing false-positive human immunodeficiency virus type 1 and other enzyme-linked immunosorbent assay results. Division of clinical pathology, Department of pathology, University of Utah (Eds). Salt lake city, Utah, USA.
- 30. Wyand, M., Manson, K., Miller, C., et all. (1999). Effect of 3-hydroxyphthaloyl-beta-lactoglobulin on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrobial Agents and Chemotherapy.

- 31. Yamauchi, K., Tomita, M., Giehl, T., et all. (1993). Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infectious Immunology.
- 32. Ye, X., Cheng, K., Ng, T. (1999). Isolation and characterization of angiogenin-1 and a novel protein designated lactogenin from bovine milk. Biochemistry and Biophysical Research Communication.
- 33. Ye, X., Ng, T. (2000a). First demonstration of lactoribonuclease, a ribonuclease from bovine milk with similarity to pancreatic ribonuclease. Life Sciences.
- 34. Ye, X., Ng, T. (2000b). Purification of a novel apolipoprotein H-like milk protein with ribonucleolytic and cell-free translation-inhibitory activities. Life Sciences.
- 35. Ye, X., Ng, T. (2000c). Purification and characterization of glycolactin, a novel glycoprotein from bovine milk. Life Sciences.
- 36. Ye, X., Wang, H., Liu, F., et all. (2000a). Ribonuclease. International Journal of Biochemistry and Cell Biology.
- 37. Ye, X., Yoshida, S., Ng, T., (2000b). Isolation of lactoperoxidase, lactoferrin, α-lactalbumin, β-lactoperoxidase, lactoferrin, β-lactoglobulin B and β-lactoglobulin A from bovine rennet whey using ion exchange chromatography. International Journal of Biochemistry and Cell Biology.
- 38. Yoshida, S., Ye, X. (1991). Isolation of lactoperoxidase and lactoferrins from bovine milk acid whey by carboxymethyl cation exchange chromatography. Journal of Dairy Sciences.